文献速递心脑血管急症重症综合管理与镇静镇痛

白蛋白锚定血栓炎症比值在动脉瘤性蛛网膜下腔出血中提供超越临床严重度评分的适度增量预后价值:一项回顾性研究

Albumin-Anchored Thromboinflammatory Ratios Provide Modest Incremental Prognostic Value Beyond Clinical Severity Scores in Aneurysmal Subarachnoid Hemorrhage: A Retrospective Study.
PubMed 文献 · Neurocrit Care · 2026-08-05
一句话结论在aSAH患者中,入院24小时内计算的DAR和CAR独立预测出院不良功能结局和院内死亡,DAR在临床模型基础上提供适度但统计学显著的增量预后价值。

这项回顾性多中心队列研究纳入212例成人放射学确诊的aSAH患者,分析入院24小时内的实验室参数。主要终点为出院时不良功能状态(mRS≥3),次要终点为院内死亡。不良功能结局发生88例(41.5%),院内死亡36例(17.0%)。多变量分析显示DAR(aOR 1.89,95%CI 1.32-2.71,p<0.001)和CAR(aOR 1.11,95%CI 1.04-1.18,p=0.002)独立预测不良功能结局。DAR加入临床模型(年龄、GCS、Hunt-Hess分级)后,对不良结局的AUC从0.89升至0.92(p=0.028),对死亡的AUC从0.91升至0.94(p=0.031),连续NRI为0.21(95%CI 0.05-0.37,p=0.012),IDI为0.028(95%CI 0.006-0.050,p=0.018)。

要点

  • 在212例aSAH患者中,入院24小时内DAR(aOR 1.89,95%CI 1.32-2.71)和CAR(aOR 1.11,95%CI 1.04-1.18)独立预测出院不良功能结局(mRS≥3)。
  • DAR预测院内死亡的AUC为0.90(95%CI 0.85-0.95),CAR预测不良功能结局的AUC为0.83(95%CI 0.77-0.89),DAR为0.86(95%CI 0.80-0.91)。
  • DAR加入年龄、GCS、Hunt-Hess临床模型后,不良结局AUC从0.89升至0.92(p=0.028),死亡AUC从0.91升至0.94(p=0.031)。
  • 重分类改善:连续NRI 0.21(95%CI 0.05-0.37,p=0.012),IDI 0.028(95%CI 0.006-0.050,p=0.018),提示增量价值适度。
  • 原文结论强调DAR的临床影响应谨慎解读,需进一步验证。

适用人群与场景

  • 成人(原文未提及具体年龄范围)放射学确诊的动脉瘤性蛛网膜下腔出血(aSAH)患者,纳入212例,来自多中心回顾性队列。
  • 排除人群原文未提及。

诊断标准与关键阈值

  • 不良功能结局定义为出院时改良Rankin量表(mRS)≥3。
  • 院内死亡为次要结局。
  • CAR为C反应蛋白/白蛋白比值,DAR为D-二聚体/白蛋白比值,均基于入院24小时内实验室参数计算;原文未提及具体阈值或界值。

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:回顾性多中心队列研究;样本量212例成人aSAH患者;多中心数量原文未提及。
  • 主要终点:出院不良功能结局(mRS≥3)发生88例(41.5%);次要终点院内死亡36例(17.0%)。
  • 多变量分析:DAR调整OR 1.89(95%CI 1.32-2.71,p<0.001),CAR调整OR 1.11(95%CI 1.04-1.18,p=0.002),均独立预测不良功能结局。
  • ROC分析:CAR预测不良功能结局AUC 0.83(95%CI 0.77-0.89),DAR AUC 0.86(95%CI 0.80-0.91);DAR预测死亡AUC 0.90(95%CI 0.85-0.95)。
  • 增量预后价值:DAR加入年龄、GCS、Hunt-Hess临床模型后,不良结局AUC从0.89升至0.92(p=0.028),死亡AUC从0.91升至0.94(p=0.031);连续NRI 0.21(95%CI 0.05-0.37,p=0.012),IDI 0.028(95%CI 0.006-0.050,p=0.018)。

证据类型、等级与局限

  • 证据类型:回顾性多中心队列研究。
  • 证据等级或推荐强度原文未提及。
  • 局限:回顾性设计、样本量212例、单中心或多中心数量未明确、增量价值适度且临床影响应谨慎解读(原文结论)。

对床旁实践的改变

  • 对于aSAH患者,入院24小时内计算的DAR和CAR可作为预后评估的辅助指标,尤其DAR在临床模型(年龄、GCS、Hunt-Hess)基础上提供适度增量价值,但原文强调临床影响应谨慎解读,不能替代临床严重度评分。
  • 原文未提及具体适用与不适用人群、常见陷阱。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: Aneurysmal subarachnoid hemorrhage (aSAH) remains associated with substantial mortality and functional disability despite advances in neurosurgical and intensive care management. Systemic inflammation and thromboinflammatory activation play key roles in early brain injury and secondary complications. We aimed to evaluate the prognostic value of albumin-anchored inflammatory ratios-C-reactive protein/Albumin ratio (CAR) and D-dimer-to-Albumin Ratio (DAR)-for predicting functional outcome and in-hospital mortality in patients with aSAH.

MATERIALS AND METHODS: In this retrospective multicenter cohort study, 212 adult patients with radiologically confirmed aSAH were included. Admission laboratory parameters obtained within the first 24 h were analyzed. The primary outcome was poor functional status at discharge (modified Rankin Scale [mRS] ≥ 3); the secondary outcome was in-hospital mortality. Univariable and multivariable logistic regression analyses were performed. Discriminatory performance was evaluated using receiver operating characteristic (ROC) analysis, and incremental prognostic value was assessed through model comparison, calibration analysis, and decision curve analysis.

RESULTS: Poor functional outcome occurred in 88 patients (41.5%), and in-hospital mortality was observed in 36 patients (17.0%). Both CAR and DAR were significantly higher in patients with poor outcomes (p < 0.001 for both). In multivariable analysis, DAR (adjusted OR 1.89, 95% CI 1.32-2.71, p < 0.001) and CAR (adjusted OR 1.11, 95% CI 1.04-1.18, p = 0.002) independently predicted poor functional outcome. ROC analysis demonstrated AUC values of 0.83 (95% CI 0.77-0.89) for CAR and 0.86 (95% CI 0.80-0.91) for DAR. For mortality prediction, DAR achieved an AUC of 0.90 (95% CI 0.85-0.95). The addition of DAR to a clinical model (age, GCS, Hunt-Hess grade) provided a modest but statistically significant improvement in discrimination for poor outcome (AUC increase from 0.89 to 0.92; p = 0.028) and mortality (AUC increase from 0.91 to 0.94; p = 0.031). Reclassification analyses showed a continuous NRI of 0.21 (95% CI 0.05-0.37; p = 0.012) and an IDI of 0.028 (95% CI 0.006-0.050; p = 0.018).

CONCLUSIONS: Albumin-anchored inflammatory ratios, particularly DAR, were independently associated with poor functional outcome and in-hospital mortality in patients with aSAH. DAR provides modest incremental prognostic information beyond established clinical severity scores, supported by improvements in reclassification metrics; however, its clinical impact should be interpreted cautiously.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Aykanat O, Sezer A, Duzenli Y, et al. Albumin-Anchored Thromboinflammatory Ratios Provide Modest Incremental Prognostic Value Beyond Clinical Severity Scores in Aneurysmal Subarachnoid Hemorrhage: A Retrospective Study. Neurocrit Care. 2026. PMID: 42557436. doi:10.1007/s12028-026-02623-y

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。